WG
CASI

Winton Group’s CASI Pharmaceuticals CASI Stock Holding History

Winton Group’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,480
Closed -$23K – 1347
2021
Q2 		$23K Sell
1,480
-566
-28% -$9.52K ﹤0.01% 1406
2021
Q1 		$49K Buy
2,046
+66
+3% +$1.85K ﹤0.01% 1352
2020
Q4 		$58K Sell
1,980
-5,703
-74% -$124K ﹤0.01% 1283
2020
Q3 		$118K Sell
7,683
-2,623
-25% -$49.4K ﹤0.01% 1389
2020
Q2 		$258K Buy
10,306
+1,753
+20% +$38.1K 0.01% 1314
2020
Q1 		$174K Buy
8,553
+2,678
+46% +$63.9K ﹤0.01% 1272
2019
Q4 		$182K Buy
5,875
+534
+10% +$17.3K ﹤0.01% 1449
2019
Q3 		$178K Buy
+5,341
New +$171K ﹤0.01% 1409
2019
Q2 		– Sell
-5,046
Closed -$145K – 1138
2019
Q1 		$145K Buy
+5,046
New +$176K ﹤0.01% 1001

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Winton Group's CASI Position: Q3 2021 in Review

Winton Group sold out of CASI Pharmaceuticals (CASI) in Q3 2021, closing a stake of 1,480 shares — an estimated $23K sold.

Winton Group first reported a position in CASI in Q1 2019 and held it in 9 quarters. The position peaked at $258K in Q2 2020. 58 funds tracked by Wall St. Rank hold CASI as of Q3 2021.

  • Winton Group reported no remaining CASI Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Winton Group sold 1,480 CASI Pharmaceuticals shares in Q3 2021, an estimated $23K.
  • Winton Group first reported a position in CASI Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Winton Group's CASI Pharmaceuticals position peaked at $258K in Q2 2020.
  • 58 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2021.

Based on Winton Group's 13F filing for Q3 2021, filed 28 Oct 2021.